![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2024/01/08/2805433/0/en/Vector-Pharma-FZCO-Announce-Exclusive-Distribution-Agreement-with-Ascendis-Pharma-A-S-for-Skytrofa-lonapegsomatropin-and-Yorvipath-palopegteriparatide-in-Gulf-Cooperation-Council-C.html
https://www.globenewswire.com//news-release/2023/12/19/2798534/0/en/TransCon-hGH-lonapegsomatropin-Achieved-Statistically-Superior-Outcomes-Compared-to-Placebo-in-Phase-3-foresiGHt-Trial-of-Adults-with-Growth-Hormone-Deficiency.html
https://www.globenewswire.com//news-release/2023/09/15/2743952/0/en/Ascendis-Pharma-Launches-SKYTROFA-lonapegsomatropin-in-Germany-for-the-Once-Weekly-Treatment-of-Children-and-Adolescents-with-Growth-Hormone-Deficiency.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761177
https://www.prnewswire.com/news-releases/visen-pharmaceuticals-announces-top-line-results-of-phase-3-trial-of-once-weekly-lonapegsomatropin-demonstrating-superior-efficacy-comparable-safety-and-tolerability-to-daily-growth-hormone-301552704.html
https://www.globenewswire.com/news-release/2022/05/01/2433059/0/en/Ascendis-Pharma-A-S-to-Present-New-Endocrinology-Results-at-Four-Medical-Meetings-in-May.html
https://www.ema.europa.eu/en/medicines/human/EPAR/lonapegsomatropin-ascendis-pharma